Progressive and Sustained Disease Control in Patients with Atopic Dermatitis (AD) Aged 12–17 Years Treated with Tralokinumab 300 mg for 52 Weeks

Objectives • To evaluate EASI response and PROs in ECZTRA 6 adolescents treated with tralokinumab 300 mg for the full 52-week treatment period. Results • Cumulative proportions of patients using concomitant TCS (any strength) as rescue therapy during the first 16 weeks were lower with tralokinumab 300 mg (29.9%) versus placebo (56.4%) • Over 52 weeks, the cumulative proportion of tralokinumab-treated patients using any TCS increased to 47.4%, as TCS were permitted as optional concomitant medication in the open-label arm • Greater proportions of tralokinumab- vs placebo-treated patients achieved primary endpoints at Week 16 (Table 1). Progressive improvement in EASI was seen through Week 52. Background • In the ECZTRA 6 (NCT03526861) phase 3 trial, tralokinumab 300 mg provided progressive and sustained efficacy in adolescent patients with moderate-to-severe AD and was well-tolerated with a reassuring long-term safety profile over 52 weeks. Methods.